• Skip to primary navigation
  • Skip to main content
Rebiotix Logo

Rebiotix

Powerful Therapy Delivered

  • Home
  • About
    • Senior Management
    • Stool Donor Program
    • Careers and Employment
  • Our Therapy
    • The Human Microbiome
    • Microbiota Restoration Therapy
    • Clostridioides difficile Infection
    • The Future of Microbiome-Based Therapeutics
  • Clinical Trials
    • RBX2660 Clinical Trials
    • RBX7455 Clinical Evaluation
    • Physician-sponsored Studies
    • Patient Resources
    • Expanded Access Policy
  • Science
    • Congress Publications
    • Manuscripts and Whitepapers
    • Related Evidence
  • Media
    • Latest Press Releases
    • Frequently Asked Questions
    • “Rebiotix” in the News
    • Conferences
    • Media Tools
    • Presentations & Videos
    • Contacts
  • Contact Us
  • Show Search
Hide Search

Does the donor matter? Donor vs patient effects in the outcome of a next generation microbiota-based drug trial for recurrent Clostridium difficile infection

Arnab Ray*1, & Courtney Jones2

1Ochsner Clinic Foundation, New Orleans, LA, USA, 2Rebiotix Inc., Roseville, MN, USA

View the article at Future Medicine
Download this Clinical trial evaluation (1 MB)
March 17, 2016

Conclusions

Based on this analysis of the PUNCH CD study, the specific donor does not affect the outcomes achieved with administration of RBX2660 for recurrent CDI. The results suggest that outcomes are patient specific and it is not necessary to switch donors in order to achieve a cure if the first dose fails, although in some cases, a second dose may be necessary. To solidify these findings, a larger study with an expanded cohort of donors whose product is again randomized to the patient is currently underway. Additional research is also needed to provide more details on patient-specific factors that could potentially impact success or failure with this therapy. Such variables could include the retention of specific antibiotics in the intestinal tract before treatment, type of antibiotic regimen used prior to treatment, additional patient comorbidities not taken into account in this study and dosage timing.

Executive Summary

  • RBX2660 (microbiota suspension processed from unrelated donors) is an effective treatment for recurring CDI.
  • Success of RBX2660 treatment was not significantly impacted by donor or dose order.
  • Results suggest that outcomes are patient specific and it is not necessary to switch donors in order to achieve a cure if the first dose fails.

Keywords: Clostridium difficile infection, fecal microbiota transplant, fecal transplantation, FMT, FT, gut microbiota, RBX2660, stool donor

Microbiota Restoration Therapy Journal Articles Journal Articles

Interested in Becoming a Stool Donor? Learn More

Rebiotix

  • Copyright © 2022 Rebiotix, Inc.
  • A Ferring Company
  • Privacy Policy
  • Terms of Use
  • Sitemap
  • Contact Us

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT